T
Tianjin Xinglian Peptide Biotechnology
ConjuStar Biotech develops innovative oncology therapies
About Tianjin Xinglian Peptide Biotechnology
Conjustar operates in the biotechnology sector, focusing on the development of miniaturized conjugated drugs to treat solid tumors. The company serves pharmaceutical companies, research institutions, and healthcare providers. Conjustar leverages its globally excellent technology platform to create novel drugs, including PDC (Peptide-Drug Conjugates) and NDC (Nanoparticle-Drug Conjugates). The business model revolves around research and development, clinical trials, and partnerships with other biotech firms and healthcare organizations. Revenue is generated through licensing agreements, research grants, and collaborative projects.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jan 2025 | $14M | $55M | Hengqin Financial Investment · Fosun Health Capital | ↗ |
| SEED✓Equity / VC | Jan 2024 | $12M | $50M | Gree Electric Appliance · Fosun Health Capital | ↗ |
Growth signals
Latest recorded traffic for Tianjin Xinglian Peptide Biotechnology is 520 monthly website visits, down 13.3% over the last three months. Tianjin Xinglian Peptide Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tianjin Xinglian Peptide Biotechnology in the Huangpu ecosystem
The Tianjin Xinglian Peptide Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- FCFosun Health Capital
- GAGree Electric Appliance
Hengqin Financial Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tianjin Xinglian Peptide Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tianjin Xinglian Peptide Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









